The Jenner Institute, University of Oxford, Roosevelt Drive, Oxford OX3 7DQ, UK.
Biotechnol Bioeng. 2012 Mar;109(3):719-28. doi: 10.1002/bit.24342. Epub 2011 Nov 6.
First-generation, E1/E3-deleted adenoviral vectors with diverse transgenes are produced routinely in laboratories worldwide for development of novel prophylactics and therapies for a variety of applications, including candidate vaccines against important infectious diseases, such as HIV/AIDS, tuberculosis, and malaria. Here, we show, for two different transgenes (both encoding malarial antigens) inserted at the E1 locus, that rare viruses containing a transgene-inactivating mutation exhibit a selective growth advantage during propagation in E1-complementing HEK293 cells, such that they rapidly become the major or sole species in the viral population. For one of these transgenes, we demonstrate that viral yield and cytopathic effect are enhanced by repression of transgene expression in the producer cell line, using the tetracycline repressor system. In addition to these transgene-inactivating mutations, one of which occurred during propagation of the pre-viral genomic clone in bacteria, and the other after viral reconstitution in HEK293 cells, we describe two other types of mutation, a small deletion and a gross rearranging duplication, in one of the transgenes studied. These were of uncertain origin, and the effects on transgene expression and viral growth were not fully characterized. We demonstrate that, together with minor protocol modifications, repression of transgene expression in HEK293 cells during viral propagation enables production of a genetically stable chimpanzee adenovirus vector expressing a malarial antigen which had previously been impossible to derive. These results have important implications for basic and pre-clinical studies using adenoviral vectors and for derivation of adenoviral vector products destined for large-scale amplification during biomanufacture.
第一代、E1/E3 缺失的腺病毒载体可以携带各种转基因,目前全球实验室都在常规生产,用于开发针对多种应用的新型预防和治疗方法,包括针对艾滋病毒/艾滋病、结核病和疟疾等重要传染病的候选疫苗。在这里,我们展示了两种不同的转基因(均编码疟原虫抗原)插入到 E1 位点,在 E1 互补 HEK293 细胞中繁殖时,含有转基因失活突变的罕见病毒表现出选择性生长优势,以至于它们迅速成为病毒群体中的主要或唯一物种。对于其中一种转基因,我们证明使用四环素阻遏系统抑制生产细胞系中转基因的表达可以增强病毒产量和细胞病变效应。除了这些转基因失活突变,其中一个突变发生在细菌中前病毒基因组克隆的繁殖过程中,另一个突变发生在 HEK293 细胞中病毒重建之后,我们还描述了在研究的一种转基因中另外两种类型的突变,一个小缺失和一个大的重排重复。这些突变的来源不确定,对转基因表达和病毒生长的影响也没有完全确定。我们证明,通过在病毒繁殖期间抑制 HEK293 细胞中转基因的表达,结合微小的方案修改,可以生产之前不可能获得的表达疟原虫抗原的遗传稳定的黑猩猩腺病毒载体。这些结果对于使用腺病毒载体进行基础和临床前研究以及对于在生物制造过程中用于大规模扩增的腺病毒载体产品的开发具有重要意义。